Odyssean LLC Makes New Investment in Denali Therapeutics Inc. $DNLI

Odyssean LLC acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 125,062 shares of the company’s stock, valued at approximately $3,217,000. Denali Therapeutics comprises 0.5% of Odyssean LLC’s portfolio, making the stock its 29th biggest position.

Other institutional investors also recently made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Denali Therapeutics during the 2nd quarter valued at $26,000. Headlands Technologies LLC bought a new stake in Denali Therapeutics in the second quarter worth $26,000. Global Retirement Partners LLC bought a new stake in Denali Therapeutics in the second quarter worth $28,000. Johnson Financial Group Inc. purchased a new stake in Denali Therapeutics during the third quarter valued at about $29,000. Finally, State of Wyoming bought a new position in shares of Denali Therapeutics during the second quarter valued at about $29,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Stock Up 3.0%

Shares of NASDAQ:DNLI opened at $24.93 on Wednesday. Denali Therapeutics Inc. has a 1 year low of $12.58 and a 1 year high of $27.30. The company has a market cap of $3.99 billion, a PE ratio of -8.78 and a beta of 1.01. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32. The stock’s 50-day moving average is $24.55 and its 200 day moving average is $21.64.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The business had revenue of $3.60 million during the quarter, compared to analyst estimates of $2.15 million. During the same period last year, the firm earned ($0.72) earnings per share. Sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.59 EPS for the current year.

Wall Street Analyst Weigh In

DNLI has been the topic of several analyst reports. Wedbush reiterated an “outperform” rating and issued a $26.00 price objective on shares of Denali Therapeutics in a report on Monday, July 13th. Wall Street Zen upgraded Denali Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. UBS Group raised their price target on Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Robert W. Baird set a $34.00 price target on Denali Therapeutics in a research note on Friday, August 7th. Finally, Morgan Stanley boosted their price objective on Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Fourteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $35.85.

Insider Activity

In related news, insider Alexander O. Schuth sold 2,857 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total transaction of $71,624.99. Following the completion of the transaction, the insider owned 281,763 shares in the company, valued at $7,063,798.41. This represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 9.70% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.